Risdiplam
Brand name: Evrysdi
Rank #253 of 500 drugs by total cost
$51.1M
Total Cost
1,891
Total Claims
$51.1M
Total Cost
67
Prescribers
$27K
Cost per Claim
0
Beneficiaries
1,926
30-Day Fills
$762K
Avg Cost/Provider
28
Avg Claims/Provider
About Risdiplam
Risdiplam (sold as Evrysdi) was prescribed 1,891 times by 67 Medicare Part D providers in 2023, costing the program $51.1M. At $27K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 250 | Clobetasol Propionate (Clobetasol Propionate) | $51.2M | 758,575 |
| 251 | Sodium,calcium,mag,pot Oxybate (Xywav) | $51.1M | 3,234 |
| 252 | Eslicarbazepine Acetate (Aptiom) | $51.1M | 31,472 |
| 253 | Risdiplam (Evrysdi) | $51.1M | 1,891 |
| 254 | Amikacin Liposomal/Neb.Accessr (Arikayce) | $50.5M | 3,394 |
| 255 | Diclofenac Epolamine (Licart) | $50.5M | 72,299 |
| 256 | Donepezil Hcl (Donepezil Hcl) | $50.3M | 3,178,215 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology